AI
RLMD icon

AdvisorShares Investments’s Relmada Therapeutics RLMD Stock Holding History

AdvisorShares Investments’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.04M Buy
438,901
+143,029
+48% +$999K 0.37% 45
2026
Q1 		$2.06M Sell
295,872
-23,638
-7% -$112K 0.38% 42
2025
Q4 		$1.54M Sell
319,510
-83,978
-21% -$281K 0.26% 53
2025
Q3 		$811K Buy
403,488
+6,974
+2% +$6.69K 0.13% 88
2025
Q2 		$238K Buy
396,514
+120,000
+43% +$61.6K 0.04% 215
2025
Q1 		$75.7K Buy
276,514
+66,446
+32% +$22K 0.01% 256
2024
Q4 		$109K Buy
210,068
+141,540
+207% +$345K 0.02% 245
2024
Q3 		$222K Sell
68,528
-21,500
-24% -$69.6K 0.04% 211
2024
Q2 		$276K Buy
90,028
+19,975
+29% +$72.3K 0.05% 207
2024
Q1 		$326K Sell
70,053
-4,613
-6% -$22.2K 0.05% 202
2023
Q4 		$309K Sell
74,666
-38,242
-34% -$113K 0.07% 204
2023
Q3 		$339K Buy
112,908
+10
+0% +$30 0.09% 167
2023
Q2 		$278K Buy
112,898
+8,758
+8% +$24.2K 0.08% 185
2023
Q1 		$235K Buy
104,140
+22,778
+28% +$78.5K 0.07% 180
2022
Q4 		$284K Buy
81,362
+70,904
+678% +$623K 0.08% 197
2022
Q3 		$387K Buy
+10,458
New +$290K 0.1% 185

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AdvisorShares Investments's RLMD Position: Q2 2026 in Review

AdvisorShares Investments increased its Relmada Therapeutics (RLMD) stake by 48% in Q2 2026, buying an estimated $999K and bringing the position to 438,901 shares worth $3.04M. The position accounts for 0.37% of the portfolio, ranked #45.

AdvisorShares Investments first reported a position in RLMD in Q3 2022 and has held it in 16 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • AdvisorShares Investments held 438,901 shares of Relmada Therapeutics worth $3.04M as of Q2 2026.
  • AdvisorShares Investments bought 143,029 Relmada Therapeutics shares in Q2 2026, an estimated $999K.
  • Relmada Therapeutics made up 0.37% of AdvisorShares Investments's portfolio in Q2 2026, its #45 holding.
  • AdvisorShares Investments first reported a position in Relmada Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on AdvisorShares Investments's 13F filing for Q2 2026, filed 11 Aug 2026.